	US 11,691,974 B2
	3,9-diazaspiro[5,5]undecane compound as FLT3 and AXL inhibitors
Xiangyu Fu, Shanghai (CN); Charles Z. Ding, Shanghai (CN); Lihong Hu, Shanghai (CN); Jianyu Lu, Shanghai (CN); Wen Jiang, Shanghai (CN); Jian Li, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to MEDSHINE DISCOVERY INC., Jiangsu (CN)
Appl. No. 17/281,479
Filed by MEDSHINE DISCOVERY INC., Jiangsu (CN)
PCT Filed Sep. 27, 2019, PCT No. PCT/CN2019/108522 § 371(c)(1), (2) Date Mar. 30, 2021, PCT Pub. No. WO2020/063856, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 201811157842.2 (CN), filed on Sep. 30, 2018; and application No. 201910193150.1 (CN), filed on Mar. 14, 2019.
Prior Publication US 2021/0395252 A1, Dec. 23, 2021
Int. Cl. C07D 405/14 (2006.01); A61K 31/497 (2006.01); C07D 471/10 (2006.01); A61P 35/02 (2006.01)

CPC C07D 471/10 (2013.01) [A61P 35/02 (2018.01)]

7 Claims

1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof,